Estrella Immunopharma (ESLA) Non Operating Investment Income (2021 - 2023)
Estrella Immunopharma (ESLA) posted quarterly Non Operating Investment Income of $220100.0 for Q2 2023, up 242.95% year-over-year from $64179.0 in Q2 2022, and up 108.05% quarter-over-quarter from $105790.0 in Q1 2023.
Estrella Immunopharma (ESLA) Non Operating Investment Income (2021 - 2023) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Non Operating Investment Income for 3 consecutive years, with $220100.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Non Operating Investment Income rose 242.95% year-over-year to $220100.0; the TTM figure through Jun 2023 stood at $912094.0 (up 1216.32% YoY), while the FY2022 annual figure was $654071.0, up 45703.29% from the prior year.
- Non Operating Investment Income improved to $220100.0 in Q2 2023 per ESLA's latest filing, from $105790.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $381891.0 in Q4 2022 and bottomed at $4.0 in Q2 2021.
- Historically, Non Operating Investment Income has averaged $109043.2 across 3 years, with a median of $64179.0 in 2022.
- Annual changes were most pronounced in 2022 — Non Operating Investment Income jumped 1604375.0% — and 2023, when it jumped 242.95%.
- Estrella Immunopharma's Non Operating Investment Income stood at $857.0 in 2021, then soared by 44461.38% to $381891.0 in 2022, then sank by 42.37% to $220100.0 in 2023.
- Business Quant data shows ESLA's Non Operating Investment Income at $220100.0 in Q2 2023, $105790.0 in Q1 2023, and $381891.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 220,100.00 |
| Jun 30, 2023 | 220,100.00 |
| Mar 31, 2023 | 105,790.00 |
| Mar 31, 2023 | 105,790.00 |
| Dec 31, 2022 | 381,891.00 |
| Dec 31, 2022 | 381,891.00 |
| Sep 30, 2022 | 204,313.00 |
| Sep 30, 2022 | 204,313.00 |
| Jun 30, 2022 | 64,179.00 |
| Jun 30, 2022 | 64,179.00 |
| Mar 31, 2022 | 3,688.00 |
| Mar 31, 2022 | 3,688.00 |
| Dec 31, 2021 | 857.00 |
| Dec 31, 2021 | 857.00 |
| Sep 30, 2021 | 567.00 |
| Sep 30, 2021 | 567.00 |
| Jun 30, 2021 | 4.00 |
| Jun 30, 2021 | 4.00 |